1. A novel single nucleotide polymorphism assay for the detection of N501Y SARS-CoV-2 variants.
- Author
-
Sandoval Torrientes, M., Castelló Abietar, C., Boga Riveiro, J., Álvarez-Argüelles, M.E., Rojo-Alba, S., Abreu Salinas, F., Costales González, I., Pérez Martínez, Z., Martín Rodríguez, G., Gómez de Oña, J., Coto García, E., and Melón García, S.
- Subjects
- *
SARS-CoV-2 - Abstract
• Development of SNPs method to discriminated SARS-CoV-2 variants. • Fast, cheap and easy N501Y detection. • Total concordance with sequencing method. The N501Y mutation in SARS-CoV-2 variants found in several strains from the UK, South Africa and Brazil has been linked to increased transmission. In order to discriminate N501Y variants quickly, a single nucleotide polymorphism (SNP) discrimination assay was designed and validated. It was then deployed prospectively in 757 nasopharyngeal swabs. Validation of the novel variant discrimination assay corroborated the results in all validation panel samples (n = 63) through sequencing. This novel variant discrimination assay was then deployed prospectively in 757 clinical nasopharyngeal swabs during the last week of January 2021. N501Y was found in 206 (27.4 %) of the samples: 94 (28.2 %) men and 112 (26.85 %) women (p = 0.73). The patients in whom it was identified had a mean age of 47.8 ± 25.8 (0–96) years, similar to that of patients without this variant: 51.7 ± 25.9 (0–104) years (p = 0.06). 501Y variant was confirmed in 34 samples by sequence method and 501 N wild type was confirmed in 67. This method is sensitive, specific, and simple to apply in any microbiology lab. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF